GNLX on Nasdaq
GENELUX Corp
American pharmaceutical preparations company based in Westlake Village.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with SYNLOGIC, INC., Azitra, Inc. or Aspire-Lakewood Holdings, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-415175.0%Operating margin3
-401812.5%Net margin3
0.0%Revenue growth, 20253
-278.5%Return on equity3
-$26.4MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$19.9M
Out of $8.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $8.0K | $8.0K | |
| Research and development | $19.9M | $19.0M | |
| General and administrative | $13.4M | $12.7M | |
| Total operating expenses | $33.2M | $31.7M | |
| Operating loss | -$33.2M | -$31.7M | |
| Interest income | $711.0K | $700.0K | |
| Bond accretion income | $358.0K | $757.0K | |
| Gain on extinguishment of accounts payable | $370.0K | ||
| Total other income | $1.1M | $1.8M | |
| Net loss | -$32.1M | -$29.9M | |
| Net loss per common share - basic | -$0.86 | -$0.95 | |
| Net loss per common share - Diluted | -$0.86 | -$0.95 | |
| Weighted Average Number of Shares Outstanding, Basic | 37.2M shares | 31.5M shares | 31.5M shares |
| Weighted Average Number of Shares Outstanding, Diluted | 37.2M shares | 31.5M shares | |
| Unrealized (loss) gain on available-for-sale securities | -$55.0K | $50.0K | |
| Comprehensive loss | -$32.2M | -$29.8M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $5.3M | $8.6M | |
| Marketable securities | $9.3M | $22.3M | |
| Prepaid expenses and other current assets | $535.0K | $653.0K | |
| Total current assets | $15.1M | $31.5M | |
| Property and equipment, net | $2.2M | $1.3M | |
| Right of use assets | $1.6M | $1.8M | |
| Other assets | $144.0K | $92.0K | |
| Total Assets | $19.0M | $34.7M | |
| Accounts payable and accrued expenses | $4.4M | $5.6M | |
| Accrued payroll and payroll taxes | $1.4M | $1.0M | |
| Lease liabilities, current portion | $427.0K | $329.0K | |
| Total current liabilities | $6.2M | $6.9M | |
| Lease liabilities, net of current portion | $1.3M | $1.5M | |
| Total liabilities | $7.5M | $8.4M | |
| Common stock, par value $0.001, 200,000,000 shares authorized; 38,139,144 and 34,728,140 shares issued and outstanding | $38.0K | $35.0K | |
| Treasury stock, 433,333 shares, at cost | -$433.0K | -$433.0K | |
| Additional paid-in capital | $295.5M | $278.0M | |
| Accumulated other comprehensive income | $9.0K | $64.0K | |
| Accumulated deficit | -$283.5M | -$251.4M | |
| Total stockholders equity | $11.5M | $26.3M | $19.5M |
| Total Liabilities and Stockholders Equity | $19.0M | $34.7M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 38.1M shares | 34.7M shares | |
| Common stock, shares outstanding | 38.1M shares | 34.7M shares | |
| Treasury stock, shares | 433.3K shares | 433.3K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $5.3M | $8.6M | |
| Marketable securities | $9.3M | $22.3M | |
| Prepaid expenses and other current assets | $535.0K | $653.0K | |
| Total current assets | $15.1M | $31.5M | |
| Property and equipment, net | $2.2M | $1.3M | |
| Right of use assets | $1.6M | $1.8M | |
| Other assets | $144.0K | $92.0K | |
| Total Assets | $19.0M | $34.7M | |
| Accounts payable and accrued expenses | $4.4M | $5.6M | |
| Accrued payroll and payroll taxes | $1.4M | $1.0M | |
| Lease liabilities, current portion | $427.0K | $329.0K | |
| Total current liabilities | $6.2M | $6.9M | |
| Lease liabilities, net of current portion | $1.3M | $1.5M | |
| Total liabilities | $7.5M | $8.4M | |
| Common stock, par value $0.001, 200,000,000 shares authorized; 38,139,144 and 34,728,140 shares issued and outstanding | $38.0K | $35.0K | |
| Treasury stock, 433,333 shares, at cost | -$433.0K | -$433.0K | |
| Additional paid-in capital | $295.5M | $278.0M | |
| Accumulated other comprehensive income | $9.0K | $64.0K | |
| Accumulated deficit | -$283.5M | -$251.4M | |
| Total stockholders equity | $11.5M | $26.3M | $19.5M |
| Total Liabilities and Stockholders Equity | $19.0M | $34.7M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 38.1M shares | 34.7M shares | |
| Common stock, shares outstanding | 38.1M shares | 34.7M shares | |
| Treasury stock, shares | 433.3K shares | 433.3K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$32.1M | -$29.9M |
| Depreciation expense | $244.0K | $235.0K |
| Accretion of discount on marketable securities | -$226.0K | -$757.0K |
| Right-of-use asset | $330.0K | $668.0K |
| Stock compensation | $5.9M | $5.7M |
| Fair value of restricted stock units | $898.0K | $2.0M |
| Cost of stock option modifications and repricing | $806.0K | $332.0K |
| Gain on extinguishment of accounts payable | -$370.0K | |
| Prepaid expenses and other assets | $66.0K | $359.0K |
| Accounts payable and accrued expenses | -$1.2M | $2.2M |
| Accrued payroll and payroll taxes | $438.0K | -$1.1M |
| Lease liability | -$337.0K | -$651.0K |
| Net cash used in operating activities | -$25.3M | -$21.2M |
| Purchases of property and equipment | -$1.1M | -$381.0K |
| Purchase of marketable securities | -$18.3M | -$29.0M |
| Proceeds from sales and maturities of marketable securities | $31.5M | $21.2M |
| Net cash provided by (used in) investing activities | $12.1M | -$8.1M |
| Proceeds from common stock issued | $9.6M | $27.7M |
| Proceeds from common stock issued in connection with the Companys equity award programs | $104.0K | $125.0K |
| Proceeds from the exercise of stock options | $14.0K | |
| Proceeds from the exercise of stock warrants | $224.0K | $688.0K |
| Net cash provided by financing activities | $9.9M | $28.5M |
| Net decrease in cash, cash equivalents and restricted cash | -$3.2M | -$853.0K |
| Unrealized (loss) gain on marketable securities | -$55.0K | $50.0K |
| Initial recognition of right-of-use asset obtained in exchange for operating lease liabilities | $153.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led GENELUX Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerThomas Zindrick Jan 25, 2023 to now8
- PresidentThomas Zindrick Jan 25, 2023 to now8
- Chief financial officerMatthew Pulisic Feb 3, 2025 to now9
- Chief financial officerLourie S. Zak Aug 30, 2023 to Dec 20, 202410
Board members and other officers (13)
- Chief Medical OfficerJason Litten Jan 7, 2026 to now11
- Chief Medical OfficerPaul Scigalla Jan 25, 2023 to Oct 21, 202412
- Associate VP, ResearchQian Zhang Jan 25, 2023 to May 2, 202313
- VP, Clinical Trial OperationsTony Yu Jan 25, 2023 to now14
- Head of QualityCaroline Jewett Jul 3, 2023 to Jul 8, 202415
- Head of RegulatoryRalph Smalling Jul 3, 2023 to now16
- Board memberGabe Woodward Jan 25, 2023 to May 2, 202317
- Board memberJames L. Tyree Jan 25, 2023 to now18
- Board memberMary Mirabelli Jan 25, 2023 to now19
- Board memberThomas Zindrick Jan 25, 2023 to now8
- Board memberJohn W. Smither Sep 13, 2023 to now20
- General counselEric Groen Jul 2, 2025 to now21
- General counselSean Ryder Jan 25, 2023 to now22
Timeline
- Jan 25, 2023New chief executive Thomas Zindrick becomes CEO8
Filings
343 filings to the SEC since October 2021: 6 annual reports, 11 quarterly reports, 31 major events, 187 insider forms, 7 large holders, 2 private raises, 99 other. The latest 20:
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 4, 20264 EDGAR
- Aug 4, 20264 EDGAR
- Aug 4, 20264 EDGAR
- Jul 2, 20264 EDGAR
- Jul 1, 2026144 EDGAR
- Jun 22, 20268-K EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 4, 20264 EDGAR
The 343 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 7 such filings since October 2021:
- Feb 17, 2026SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G
- Jul 25, 2025SCHEDULE 13G/A
- Oct 25, 2024SC 13G
- Oct 22, 2024SC 13G/A
- Feb 2, 2024SC 13G
- Jun 20, 2023SC 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 72. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 2,262,108 | $6.8M | 3.0% | +144,925 |
| Vanguard Capital Management LLC | 1,677,724 | $5.0M | 0.0% | −17,756 |
| Bleichroeder LP | 1,380,666 | $4.2M | 0.7% | No change |
| BlackRock, Inc. | 439,602 | $1.3M | 0.0% | +33,730 |
| Geode Capital Management, LLC | 439,213 | $1.3M | 0.0% | −14,548 |
| CM Management, LLC | 400,000 | $1.2M | 0.8% | +150,000 |
| Bank Of America Corp /de/ | 328,803 | $989.7K | 0.0% | +4,938 |
| Vanguard Fiduciary Trust Co | 236,344 | $711.4K | 0.0% | −15,266 |
| Flputnam Investment Management Co | 231,405 | $696.5K | 0.0% | −49,499 |
| Global Retirement Partners, LLC | 227,854 | $685.8K | 0.0% | New |
| LPL Financial LLC | 157,857 | $475.1K | 0.0% | +18,816 |
| State Street Corp | 145,850 | $439.0K | 0.0% | No change |
| Provident Wealth Management, LLC | 144,908 | $436.2K | 0.1% | −10,762 |
| LifeSteps Financial, Inc. | 121,965 | $367.1K | 0.2% | +3,103 |
| Osaic Holdings, Inc. | 121,958 | $367.1K | 0.0% | +2,950 |
| Renaissance Technologies LLC | 105,229 | $316.7K | 0.0% | +93,029 |
| Northern Trust Corp | 89,279 | $268.7K | 0.0% | −75,177 |
| Citadel Advisors LLC | 85,481 | $257.3K | 0.0% | New |
| Morgan Stanley | 83,543 | $251.5K | 0.0% | −4,505 |
| SteelPeak Wealth, LLC | 75,895 | $228.4K | 0.0% | +15,000 |
| AMG National Trust Bank | 75,351 | $226.8K | 0.0% | No change |
| Falcon Wealth Planning | 63,185 | $190.2K | 0.0% | No change |
| Mariner, LLC | 52,866 | $159.1K | 0.0% | +25,000 |
| Quadrature Capital Ltd | 45,881 | $138.1K | 0.0% | New |
| Goldman Sachs Group Inc | 45,809 | $137.9K | 0.0% | +13,199 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARGENELUX Corp filings on SEC EDGAR
- 2SEC EDGARGENELUX Corp filings on SEC EDGAR
- 3SEC EDGARGENELUX Corp 10-K for fiscal 2025
- 4SEC EDGARGENELUX Corp 10-K for fiscal 2022
- 5SEC EDGARGENELUX Corp 10-K for fiscal 2023
- 6SEC EDGARGENELUX Corp 10-Q for fiscal 2026
- 7SEC EDGARGENELUX Corp 10-Q for fiscal 2026
- 8
- 9
- 10
- 11SEC EDGARJason Litten, Chief Medical Officer
- 12SEC EDGARPaul Scigalla, Chief Medical Officer
- 13SEC EDGARQian Zhang, Associate VP, Research
- 14
- 15SEC EDGARCaroline Jewett, Head of Quality
- 16SEC EDGARRalph Smalling, Head of Regulatory
- 17SEC EDGARGabe Woodward, Board member
- 18SEC EDGARJames L. Tyree, Board member
- 19SEC EDGARMary Mirabelli, Board member
- 20SEC EDGARJohn W. Smither, Board member
- 21SEC EDGAREric Groen, General counsel
- 22SEC EDGARSean Ryder, General counsel